Scarica l'app Stockscreener
40.91
0.47%
0.19
Pre-mercato:
40.03
-0.88
-2.15%
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Analysts Offer Predictions for JANX FY2025 Earnings - MarketBeat
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8% - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Trading Down 3.5%Time to Sell? - MarketBeat
Long Term Trading Analysis for (JANX) - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Shares Down 3.5%Time to Sell? - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
JANX Makes Notable Cross Below Critical Moving Average - Nasdaq
BTIG affirms Buy on Janux stock, noting competitive positioning of JANX007 in mCRPC - Investing.com Canada
Janux Therapeutics (NASDAQ:JANX) Given "Outperform" Rating at William Blair - MarketBeat
Cancer data drive significant biopharma stock gains in a volatile 2024 - BioWorld Online
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock - MarketBeat
Janux Therapeutics CEO David Campbell sells $300,004 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CEO David Campbell sells $300,004 in stock - Investing.com India
Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results - Citeline News & Insights
Janux Therapeutics (NASDAQ:JANX) Shares Down 6.8%Here's Why - MarketBeat
Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha
Janux Therapeutics (NASDAQ:JANX) Trading Up 7%Still a Buy? - MarketBeat
Objective long/short (JANX) Report - Stock Traders Daily
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of Stock - MarketBeat
Janux Therapeutics chief business officer sells $731,785 in stock By Investing.com - Investing.com Canada
Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN
Viking stock among buyout targets: Oppenheimer (VKTX:NASDAQ) - Seeking Alpha
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
Lifesci Capital Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-Buy - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,404,750.00 in Stock - MarketBeat
Janux therapeutics CEO David Campbell sells $1.4 million in stock By Investing.com - Investing.com Nigeria
Janux therapeutics CEO David Campbell sells $1.4 million in stock - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Geode Capital Management LLC - MarketBeat
How the (JANX) price action is used to our Advantage - Stock Traders Daily
StockWatch: Wall Street’s Leaders and Laggards of 2024 - Genetic Engineering & Biotechnology News
Wellington Management Group LLP Trims Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $89.90 - MarketBeat
State Street Corp Sells 40,056 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Barclays PLC - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Scrip
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Nets $350M in Stock Sale - San Diego Business Journal
Neo Ivy Capital Management Buys Shares of 20,674 Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Navigating 10 Analyst Ratings For Janux Therapeutics - Benzinga
Charles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Polar Asset Management Partners Inc. Buys New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Point72 Asset Management L.P. Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - StockTitan
Revolution , Janux prep for next steps with follow-on cash - BioCentury
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to $350 Million Underwritten Public Offering - Wilson Sonsini
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
Janux Therapeutics prices $350M securities offering - MSN
Readystate Asset Management LP Acquires New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
JANX Stock Hits Record High on Prostate Cancer Study Data - MSN
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):